Cargando…

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort

BACKGROUND: Real-life data on access and response to direct antiviral agents (DAA) in HIV-HCV coinfected individuals are lacking. METHODS: HCV viremic, HIV-positive patients from Icona and Hepaicona cohorts naïve to DAA by January 2013 were included. Access and predictors of starting DAA were evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	d'Arminio Monforte, Antonella, Cozzi-Lepri, Alessandro, Ceccherini-Silberstein, Francesca, De Luca, Andrea, Lo Caputo, Sergio, Castagna, Antonella, Mussini, Cristina, Cingolani, Antonella, Tavelli, Alessandro, Shanyinde, Milensu, Gori, Andrea, Girardi, Enrico, Andreoni, Massimo, Antinori, Andrea, Puoti, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435319/ https://www.ncbi.nlm.nih.gov/pubmed/28520749 http://dx.doi.org/10.1371/journal.pone.0177402

Ejemplares similares

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study
por: Spaziante, Martina, et al.
Publicado: (2021)

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study
por: Marchetti, Giulia, et al.
Publicado: (2014)

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
por: Malagnino, Vincenzo, et al.
Publicado: (2020)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?
por: Shanyinde, Milensu, et al.
Publicado: (2019)

HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients
por: Saracino, Annalisa, et al.
Publicado: (2018)

High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort
por: Squillace, Nicola, et al.
Publicado: (2016)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort
por: Cingolani, A, et al.
Publicado: (2015)

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2016)

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2020)

Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy
por: Nozza, Silvia, et al.
Publicado: (2021)

Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy
por: Cingolani, Antonella, et al.
Publicado: (2022)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus
por: Mussini, Cristina, et al.
Publicado: (2015)

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort
por: Nozza, Silvia, et al.
Publicado: (2017)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis
por: Girardi, Enrico, et al.
Publicado: (2012)

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era
por: Madeddu, Giordano, et al.
Publicado: (2021)

Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population
por: Cingolani, Antonella, et al.
Publicado: (2017)

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
por: Di Biagio, Antonio, et al.
Publicado: (2016)

HIV-Infected Late Presenter Patients
por: D'Arminio Monforte, Antonella, et al.
Publicado: (2012)

Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression
por: Castagna, Antonella, et al.
Publicado: (2016)

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study
por: Mussini, Cristina, et al.
Publicado: (2018)

Reply to Manfredi
por: Lichtner, Miriam, et al.
Publicado: (2015)

Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss
por: Mussini, Cristina, et al.
Publicado: (2021)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
por: Costarelli, Silvia, et al.
Publicado: (2016)

CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy
por: Madeddu, Giordano, et al.
Publicado: (2014)

Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy
por: Fabeni, Lavinia, et al.
Publicado: (2020)

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study
por: Antinori, Andrea, et al.
Publicado: (2016)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy
por: Bandera, Alessandra, et al.
Publicado: (2015)

A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy
por: Bai, Francesca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2hap5eansvqirerr9f3ugam8ee